Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service radiofrequency ablation (facet, genicular, basivertebral) cases in Ohio: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (252 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 180 | 14,240 | 47% |
| 2020 | 171 | 13,972 | 50% |
| 2021 |
Facet, genicular, and basivertebral nerve ablation. Professional codes (what the surgeon bills): CPT 64635, 64633, 64624, 64625, 64628.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 22% of the cases CMS names in Ohio; 95 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Peripheral nerve stimulation & intrathecal pumps | 26 | 1,792+4.2%/yr | +4.2%/yr | 1.51.5× | 20% | 2,660 in 2030+6.8%/yr |
| Spinal cord & DRG stimulation |
Radiofrequency ablation (facet, genicular, basivertebral) in every state, and its device makers · Every procedure market in Ohio · Every state · Compare with Illinois
| 2025 est. |
| ≈ 11,200 |
| – |
| 2026 est. | ≈ 11,400 | – |
| 187 |
| 15,439 |
| 53% |
| 2022 | 184 | 13,751 | 56% |
| 2023 | 183 | 12,172 | 58% |
| 2024 | 179 | 10,830 | 60% |
| 2025 from claims | – | 11,151 10,233–11,797 | 61% |
| 2026 forecast | – | 11,445 10,069–13,207 | 61% |
| 2027 forecast | – | 11,486 9,819–13,688 | 61% |
| 2028 forecast | – | 11,526 9,618–14,114 | 61% |
| 2029 forecast | – | 11,566 9,446–14,504 | 62% |
| 2030 forecast | – | 11,604 9,296–14,870 | 62% |
In 2025, 57% hospital outpatient, 22% surgery center, 21% office.
| 7,269−3.7%/yr |
| −3.7%/yr |
| 8.1 |
| 75% |
| 8,240 in 2030+2.1%/yr |
| Indiana | 117 | 6,614−1.7%/yr | −1.7%/yr | 9.0 | 71% | 8,050 in 2030+3.3%/yr |
| Missouri | 93 | 6,170+1.6%/yr | +1.6%/yr | 9.5 | 28% | 8,640 in 2030+5.8%/yr |
| Wisconsin | 107 | 5,630−0.5%/yr | −0.5%/yr | 9.5 | 45% | 6,580 in 2030+2.6%/yr |
| Minnesota | 88 | 4,824+0.9%/yr | +0.9%/yr | 10.1 | 73% | 6,880 in 2030+6.1%/yr |
| Kansas | 57 | 3,413+4%/yr | +4%/yr | 8.2 | 46% | 4,450 in 2030+4.5%/yr |
| Nebraska | 37 | 2,646+7.2%/yr | +7.2%/yr | 9.8 | 71% | 4,000 in 2030+7.1%/yr |
| Iowa | 36 | 2,386+2.2%/yr | +2.2%/yr | 5.2 | 62% | 2,800 in 2030+2.7%/yr |
| South Dakota | 16 | 1,153−1.6%/yr | −1.6%/yr | 8.6 | 12% | 1,270 in 2030+1.6%/yr |
| North Dakota | 12 | 670−3.9%/yr | −3.9%/yr | 6.5 | 37% | 740 in 2030+1.8%/yr |
| 22 |
| 900−1.9%/yr |
| −1.9%/yr |
| 0.71.1× |
| 32% |
| 1,040 in 2030+2.4%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Boston Scientific leads with 58% of company spending on these surgeons in 2025, +21 pts on 2024.
In 2025, 8 companies reported engagement with Ohio’s surgeons worth $165K in consulting, speaking, meals and travel tied to these products, about $922 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 2 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.